Matchpoint Therapeutics, a biotechnology firm specializing in precision covalent medicines, has entered into an exclusive option and license agreement with Novartis to develop and commercialize oral covalent inhibitors targeting a transcription factor associated with multiple inflammatory diseases. The collaboration aims to leverage Matchpoint’s proprietary Advanced Covalent Exploration (ACE) platform to target a novel binding site on a protein previously considered difficult to drug, with th...